ATE507846T1 - Aus mehreren komponenten bestehende anordnung mit verbesserten bindungseigenschaften zur diagnose und therapie - Google Patents
Aus mehreren komponenten bestehende anordnung mit verbesserten bindungseigenschaften zur diagnose und therapieInfo
- Publication number
- ATE507846T1 ATE507846T1 AT02761334T AT02761334T ATE507846T1 AT E507846 T1 ATE507846 T1 AT E507846T1 AT 02761334 T AT02761334 T AT 02761334T AT 02761334 T AT02761334 T AT 02761334T AT E507846 T1 ATE507846 T1 AT E507846T1
- Authority
- AT
- Austria
- Prior art keywords
- binding
- diagnosis
- therapy
- multiple component
- component arrangement
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasonic imaging preparations
- A61K49/222—Echographic preparations; Ultrasonic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
- A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6925—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Acoustics & Sound (AREA)
- Radiology & Medical Imaging (AREA)
- Nanotechnology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Adhesives Or Adhesive Processes (AREA)
- Multicomponent Fibers (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
- Absorbent Articles And Supports Therefor (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/932,291 US7087212B2 (en) | 2001-08-17 | 2001-08-17 | Multicomponent assemblies having enhanced binding properties for diagnosis and therapy |
| PCT/US2002/025582 WO2003015606A2 (en) | 2001-08-17 | 2002-08-13 | Multicomponent assemblies having enhanced binding properties for diagnosis and therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE507846T1 true ATE507846T1 (de) | 2011-05-15 |
Family
ID=25462092
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02761334T ATE507846T1 (de) | 2001-08-17 | 2002-08-13 | Aus mehreren komponenten bestehende anordnung mit verbesserten bindungseigenschaften zur diagnose und therapie |
Country Status (9)
| Country | Link |
|---|---|
| US (6) | US7087212B2 (de) |
| EP (1) | EP1465666B1 (de) |
| JP (2) | JP2005506974A (de) |
| AT (1) | ATE507846T1 (de) |
| AU (1) | AU2002326610A1 (de) |
| CA (1) | CA2456327C (de) |
| DE (1) | DE60239961D1 (de) |
| ES (1) | ES2365725T3 (de) |
| WO (1) | WO2003015606A2 (de) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7087212B2 (en) * | 2001-08-17 | 2006-08-08 | Mallinckrodt, Inc | Multicomponent assemblies having enhanced binding properties for diagnosis and therapy |
| WO2003097658A2 (en) | 2002-05-16 | 2003-11-27 | Glycomimetics, Inc. | Compounds and methods for inhibiting selectin-mediated function |
| JP2006502986A (ja) * | 2002-07-03 | 2006-01-26 | グリコミメティクス， インコーポレイテッド | 新脈管形成に関与する医学的状態の診断および治療のための組成物および方法 |
| US20040219158A1 (en) * | 2003-05-02 | 2004-11-04 | Glycomimetics, Inc. | Compositions and methods for diagnosis and therapy of medical conditions involving infection with pseudomonas bacteria |
| EP1763533B1 (de) * | 2003-11-19 | 2008-01-09 | GlycoMimetics, Inc. | Spezifischer antagonist sowohl für e- als auch p-selektine |
| WO2005054264A2 (en) * | 2003-11-19 | 2005-06-16 | Glycomimetics, Inc. | Glycomimetic antagonists for both e- and p-selectins |
| US8201377B2 (en) * | 2004-11-05 | 2012-06-19 | Faus Group, Inc. | Flooring system having multiple alignment points |
| US20090036386A1 (en) * | 2005-05-25 | 2009-02-05 | Glycomimetics, Inc | Heterobifunctional compounds for selectin inhibition |
| CN101291946B (zh) * | 2005-08-09 | 2011-06-29 | 糖模拟物有限公司 | 对来自假单胞菌的pa-il凝集素、pa-iil凝集素或其两者的糖模拟物抑制剂 |
| PL2264043T3 (pl) | 2005-09-02 | 2018-04-30 | Glycomimetics, Inc. | Heterobifunkcyjne inhibitory pan-selektyny |
| US20090176717A1 (en) * | 2006-06-01 | 2009-07-09 | Glycomimetics, Inc. | Galactosides and thiodigalactosides as inhibitors of pa-il lectin from pseudomonas |
| EP2074132B1 (de) | 2006-10-12 | 2013-05-15 | GlycoMimetics, Inc. | Glycomimetischer ersatz für hexosen und n-acetyl-hexosamine |
| AU2008216794A1 (en) * | 2007-02-09 | 2008-08-21 | Glycomimetics, Inc. | Methods of use of glycomimetics with replacements for hexoses and N-acetyl hexosamines |
| US8039442B2 (en) | 2007-07-18 | 2011-10-18 | Glycomimetics, Inc. | Compounds and methods for treatment of sickle cell disease or complications associated therewith |
| WO2009126556A1 (en) | 2008-04-08 | 2009-10-15 | Glycomimetics, Inc. | Pan-selectin inhibitor with enhanced pharmacokinetic activity |
| CN102088983B (zh) * | 2008-06-13 | 2013-01-30 | 糖模拟物有限公司 | 利用选择的糖模拟化合物的血液癌症的治疗 |
| US20100068266A1 (en) * | 2008-09-16 | 2010-03-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Ex vivo-modifiable multiple-release state final dosage form |
| US20100069887A1 (en) * | 2008-09-16 | 2010-03-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Multiple chamber ex vivo adjustable-release final dosage form |
| US20100160731A1 (en) * | 2008-12-22 | 2010-06-24 | Marc Giovannini | Ultrasound-visualizable endoscopic access system |
| US20100178245A1 (en) * | 2009-01-13 | 2010-07-15 | Arnsdorf Morton F | Biocompatible Microbubbles to Deliver Radioactive Compounds to Tumors, Atherosclerotic Plaques, Joints and Other Targeted Sites |
| CA2760292A1 (en) | 2009-05-01 | 2010-11-04 | Glycomimetics, Inc. | Heterobifunctional inhibitors of e-selectins and cxcr4 chemokine receptors |
| US8829020B2 (en) | 2009-07-16 | 2014-09-09 | Mallinckrodt Llc | Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers |
| US8921328B2 (en) | 2010-09-14 | 2014-12-30 | Glycomimetics, Inc. | E-selectin antagonists |
| KR102055958B1 (ko) | 2011-12-22 | 2019-12-13 | 글리코미메틱스, 인크. | E-셀렉틴 길항제 화합물, 조성물, 및 이용 방법 |
| US9867841B2 (en) | 2012-12-07 | 2018-01-16 | Glycomimetics, Inc. | Compounds, compositions and methods using E-selectin antagonists for mobilization of hematopoietic cells |
| WO2014204593A1 (en) | 2013-05-31 | 2014-12-24 | Cook Medical Technologies Llc | Access needles and stylet assemblies |
| EP3209957B1 (de) * | 2014-10-21 | 2021-04-07 | LG Electronics Inc. | Abtauvorrichtung und kühlschrank damit |
| JP6689854B2 (ja) | 2014-12-03 | 2020-04-28 | グリコミメティクス， インコーポレイテッド | Ｅ−セレクチンおよびｃｘｃｒ４ケモカイン受容体のヘテロ二官能性阻害剤 |
| JP2019502727A (ja) | 2016-01-22 | 2019-01-31 | グリコミメティクス， インコーポレイテッド | Ｐａ−ｉｌおよび／またはｐａ−ｉｉｌレクチンの糖模倣体阻害剤 |
| WO2017151708A1 (en) | 2016-03-02 | 2017-09-08 | Glycomimetics, Inc. | Methods for the treatment and/or prevention of cardiovescular disease by inhibition of e-selectin |
| US11433086B2 (en) | 2016-08-08 | 2022-09-06 | Glycomimetics, Inc. | Combination of T-cell checkpoint inhibitors with inhibitors of e-selectin or CXCR4, or with heterobifunctional inhibitors of both E-selectin and CXCR4 |
| AU2017341065B2 (en) | 2016-10-07 | 2023-04-06 | Crescent Biopharma, Inc. | Highly potent multimeric E-selectin antagonists |
| EP3596096A1 (de) | 2017-03-15 | 2020-01-22 | GlycoMimetics, Inc. | Galactopyranosyl-cyclohexyl-derivate als e-selectin-antagonisten |
| JP7275131B2 (ja) | 2017-11-30 | 2023-05-17 | グリコミメティクス， インコーポレイテッド | 骨髄浸潤リンパ球を動員する方法、およびその使用 |
| KR20200104889A (ko) | 2017-12-29 | 2020-09-04 | 글리코미메틱스, 인크. | E-셀렉틴 및 갈렉틴-3의 이종이기능성 억제제 |
| KR20200128025A (ko) | 2018-03-05 | 2020-11-11 | 글리코미메틱스, 인크. | 급성 골수성 백혈병 및 관련 병태의 치료 방법 |
| US11845771B2 (en) | 2018-12-27 | 2023-12-19 | Glycomimetics, Inc. | Heterobifunctional inhibitors of E-selectin and galectin-3 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4247406A (en) | 1979-04-23 | 1981-01-27 | Widder Kenneth J | Intravascularly-administrable, magnetically-localizable biodegradable carrier |
| DE68912139T2 (de) | 1988-11-09 | 1994-04-28 | Colin Tilcock | Liposomale radiologische kontrastmittel. |
| US5733572A (en) | 1989-12-22 | 1998-03-31 | Imarx Pharmaceutical Corp. | Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles |
| US5542935A (en) | 1989-12-22 | 1996-08-06 | Imarx Pharmaceutical Corp. | Therapeutic delivery systems related applications |
| US6001335A (en) | 1989-12-22 | 1999-12-14 | Imarx Pharmaceutical Corp. | Contrasting agents for ultrasonic imaging and methods for preparing the same |
| US5580575A (en) | 1989-12-22 | 1996-12-03 | Imarx Pharmaceutical Corp. | Therapeutic drug delivery systems |
| JPH03297475A (ja) | 1990-04-16 | 1991-12-27 | Ken Ishihara | 共振音波により薬物の放出を制御する方法 |
| CA2102605A1 (en) | 1991-05-23 | 1992-11-24 | Evan C. Unger | Liposoluble compounds for magnetic resonance imaging |
| GB9200387D0 (en) * | 1992-01-09 | 1992-02-26 | Nycomed As | Improvements in or relating to contrast agents |
| US5648062A (en) * | 1992-01-09 | 1997-07-15 | Nycomed Imaging As | Contrast agents consisting of galactose particles |
| PL312387A1 (en) | 1993-07-02 | 1996-04-15 | Molecular Biosystems Inc | Proteinous microbeads of encapsulated non-dissolving gas and method of making them and their application as ultrasonic visualisation medium |
| IL106887A (en) | 1993-09-02 | 1997-02-18 | Yissum Res Dev Co | Pharmaceutical and diagnostic compositions and a method for drug targeting |
| JP2828391B2 (ja) * | 1993-10-29 | 1998-11-25 | 東燃株式会社 | オリゴ糖を表面に有するリポソーム |
| CA2178476A1 (en) | 1993-12-07 | 1995-06-15 | Neorx Corporation | Pretargeting methods and compounds |
| GB9420390D0 (en) * | 1994-10-10 | 1994-11-23 | Nycomed Salutar Inc | Liposomal agents |
| US5543133A (en) | 1995-02-14 | 1996-08-06 | Nanosystems L.L.C. | Process of preparing x-ray contrast compositions containing nanoparticles |
| US5510118A (en) | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
| EP0831932B1 (de) * | 1995-06-07 | 2004-05-06 | Imarx Pharmaceutical Corp. | Neue zielgerichtete mittel zur diagnostischen und therapeutischen verwendung |
| CA2247115C (en) | 1996-03-01 | 2008-11-18 | The Regents Of The University Of California | Inhibition of selectin binding |
| WO1998018501A2 (en) * | 1996-10-28 | 1998-05-07 | Marsden, John, Christopher | Improvements in or relating to diagnostic/therapeutic agents |
| US6331289B1 (en) * | 1996-10-28 | 2001-12-18 | Nycomed Imaging As | Targeted diagnostic/therapeutic agents having more than one different vectors |
| AU733495B2 (en) * | 1996-10-28 | 2001-05-17 | Nycomed Imaging As | Improvements in or relating to diagnostic/therapeutic agents |
| GB9708265D0 (en) * | 1997-04-24 | 1997-06-18 | Nycomed Imaging As | Contrast agents |
| ATE314097T1 (de) * | 1996-10-28 | 2006-01-15 | Amersham Health As | Kontrastmittel |
| WO1998040285A1 (en) | 1997-03-13 | 1998-09-17 | Minnesota Mining And Manufacturing Company | Sample package |
| JP2003508499A (ja) * | 1999-09-08 | 2003-03-04 | インスティテュート・フュア・ディアグノスティクフォルシュンク・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング・アン・デア・フライエン・ウニヴエアズィテート・ベルリン | Ｌ−セレクチン造影剤 |
| US7087212B2 (en) * | 2001-08-17 | 2006-08-08 | Mallinckrodt, Inc | Multicomponent assemblies having enhanced binding properties for diagnosis and therapy |
| US6733572B2 (en) * | 2002-07-30 | 2004-05-11 | Exxonmobil Chemical Patents Inc. | Separation of propylene and dimethylether from hydrocarbon mixtures |
-
2001
- 2001-08-17 US US09/932,291 patent/US7087212B2/en not_active Expired - Lifetime
-
2002
- 2002-08-13 AT AT02761334T patent/ATE507846T1/de not_active IP Right Cessation
- 2002-08-13 JP JP2003520371A patent/JP2005506974A/ja active Pending
- 2002-08-13 WO PCT/US2002/025582 patent/WO2003015606A2/en not_active Ceased
- 2002-08-13 DE DE60239961T patent/DE60239961D1/de not_active Expired - Lifetime
- 2002-08-13 AU AU2002326610A patent/AU2002326610A1/en not_active Abandoned
- 2002-08-13 ES ES02761334T patent/ES2365725T3/es not_active Expired - Lifetime
- 2002-08-13 EP EP02761334A patent/EP1465666B1/de not_active Expired - Lifetime
- 2002-08-13 CA CA2456327A patent/CA2456327C/en not_active Expired - Fee Related
-
2006
- 2006-08-04 US US11/462,591 patent/US7713514B2/en not_active Expired - Fee Related
-
2009
- 2009-09-04 JP JP2009205352A patent/JP2009280625A/ja not_active Withdrawn
- 2009-10-23 US US12/603,402 patent/US8257683B2/en not_active Expired - Fee Related
- 2009-10-23 US US12/603,438 patent/US8246930B2/en not_active Expired - Fee Related
-
2010
- 2010-07-12 US US12/834,463 patent/US8303932B2/en not_active Expired - Fee Related
- 2010-07-12 US US12/834,521 patent/US8303933B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US8246930B2 (en) | 2012-08-21 |
| JP2005506974A (ja) | 2005-03-10 |
| EP1465666A2 (de) | 2004-10-13 |
| US20030039683A1 (en) | 2003-02-27 |
| AU2002326610A1 (en) | 2003-03-03 |
| US7713514B2 (en) | 2010-05-11 |
| US8303933B2 (en) | 2012-11-06 |
| DE60239961D1 (de) | 2011-06-16 |
| US20060269511A1 (en) | 2006-11-30 |
| US8303932B2 (en) | 2012-11-06 |
| EP1465666A4 (de) | 2005-11-30 |
| US20100041827A1 (en) | 2010-02-18 |
| JP2009280625A (ja) | 2009-12-03 |
| US20100280232A1 (en) | 2010-11-04 |
| US20100280177A1 (en) | 2010-11-04 |
| CA2456327A1 (en) | 2003-02-27 |
| WO2003015606A3 (en) | 2004-08-12 |
| ES2365725T3 (es) | 2011-10-10 |
| EP1465666B1 (de) | 2011-05-04 |
| CA2456327C (en) | 2011-11-29 |
| WO2003015606A2 (en) | 2003-02-27 |
| US20100041826A1 (en) | 2010-02-18 |
| US7087212B2 (en) | 2006-08-08 |
| US8257683B2 (en) | 2012-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE507846T1 (de) | Aus mehreren komponenten bestehende anordnung mit verbesserten bindungseigenschaften zur diagnose und therapie | |
| EA200000848A1 (ru) | Способ селективного снижения числа или активности макрофагов (варианты), способ лечения или профилактики заболевания субъекта (варианты), способ диагностики заболевания у субъекта | |
| WO2007134037A3 (en) | Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments | |
| WO2007006041A3 (en) | Imaging and therapeutic method using monocytes | |
| WO2002053177A3 (en) | Agents and methods for treating pain | |
| WO2006079120A3 (en) | Fc-fusion constructs binding to phosphatidylserine and their therapeutic use | |
| EP2535355A3 (de) | Antikörper gegen CD38 zur Behandling von multiplem Myelom | |
| WO2002046222A3 (en) | Compositions and methods for diagnosing alzheimer's disease | |
| IL169896A0 (en) | Methods and compositions for administering therapeutic and diagnostic agents | |
| EP4279140A3 (de) | Humane antikorper gegen humanen gewebefaktor | |
| ATE267798T1 (de) | Kombinierte wirkstoffe als methode zur gezielten wirkstoff-freisetzung | |
| WO2005079391A3 (en) | Contrast agents for myocardial perfusion imaging | |
| ATE335515T1 (de) | Morpholinobildgebung und therapie | |
| EP2253333A3 (de) | Kontrastmittel für die blidgebende perfusion | |
| PT1381611E (pt) | Analogos de ftalocianina substituidas com metal sem centro de simetria sua preparacao e uso em terapia fotodinamica e em diagnostico in vivo | |
| WO2002087497A3 (en) | Therapeutic agent/ligand conjugate compositions, their methods of synthesis and use | |
| TR199902775T2 (xx) | 20(S)-Kamptotesin glikokonjugeleri. | |
| NZ524329A (en) | IgE receptor antagonists that compete with IgE134 for binding to the receptor | |
| MXPA05006306A (es) | Agentes de direccionamiento antilinfoma con funciones efectoras y de afinidad enlazados a traves de un reactivo trifuncional. | |
| WO2003102185A3 (en) | Methods and compositions for treating neoplasia relating to hnrnp a1 and a2 nucleic acid molecules | |
| ATE364315T1 (de) | Tgf-alpha polypeptide, funktionelle fragmente und verfahren zu ihrer anwendung | |
| IL159479A (en) | Glycopeptides, their preparation and use in the diagnosis or therapeutic treatment of multiple sclerosis | |
| SE0203731D0 (sv) | Reagent | |
| WO2001008708A3 (en) | Enhanced delivery via serpin enzyme complex receptor ligands | |
| WO2002062300A3 (en) | Cholesterol-lowering agents as treatment for psychological and cognitive disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |